Altamira Therapeutics News and Activities

Altamira Therapeutics is a company listed under the stock ticker EARS (CH).

View the org chart displaying its 8 main executives

Most searched biographies at Altamira Therapeutics

• Thomas Meyer, Chief Executive Officer and Chairman of the Board
• Alain Munoz, Director
• Dominik Lysek, Director

Popular executive movements at Altamira Therapeutics

• Mario Barbieri, Head, Finance and Administration, has left the company  (posted on June 26 2026).

Create your alert
to follow the executive moves at Altamira Therapeutics.

Altamira Therapeutics has 1,919 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Catalyst Pharmaceuticals, listed under ticker CPRX, has been delisted. (posted on July 13 2026).
• Angelini Pharma has acquired Catalyst Pharmaceuticals (posted on July 13 2026).
• Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals  (posted on July 7 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Richard Saynor - Chief Executive Officer at Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson

Learn more about the Pharmaceuticals industry

Press releases by Altamira Therapeutics

• Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business | Altamira Therapeutics
• Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine | Altamira Therapeutics
• Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis | Altamira Therapeutics
• Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results | Altamira Therapeutics
• Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th | Altamira Therapeutics
• Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 | Altamira Therapeutics
• Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia | Altamira Therapeutics
• Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal | Altamira Therapeutics
• Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering | Altamira Therapeutics
• Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration | Altamira Therapeutics
• View more press releases Close

Social media about Altamira Therapeutics

• Altamira Therapeutics on Wikipedia, Google News & Yahoo Finance
• Altamira Therapeutics on LinkedIn, X (Twitter) & YouTube